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Abstract  
 Sexual dysfunction is a common, underappreciated complication of 
diabetes. Male sexual dysfunction among diabetic patients can include 
disorders of libido, ejaculatory problems, and erectile dysfunction (ED). All 
three forms of male dysfunction can cause significant bother for diabetic 
patients and can affect their quality of life. Diabetic patients take oral 
hypoglycemic drug to control their diabetic as well as take herbal sex 
stimulants to control to increase the libido. The combined use of herbs and 
drugs has increased the possibility of herb-drug interactions. The study was 
undertaken to explore the herb-drug interactions. To investigate the herb-
drug interactions an in vitro dissolution study in different simulated pH 
medium were performed. In this study gliclazide containing tablet of 80mg 
as oral hypoglycemic drug and different herbal sex stimulants available in 
local market were used. The release mechanism was explored and explained 
with zero order, first order and Higuchi equations to identify drug 
interaction. Higher percentage release of gliclazide was found at simulated 
phosphate buffer of pH 7.4 compared to gastric medium of pH 1.2 and also 
in presence of herbal sex stimulants. Increased release pattern of gliclazide 
European Scientific Journal March 2016 edition vol.12, No.9  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
239 
by concomitant administration of herbal sex stimulants gives slightly higher 
absorption, which gives the indication of herb-drug interactions.  
 




 Millions of people today use herbal therapies along with prescription 
and nonprescription medications. Although considered natural, many of 
these herbal therapies can interact with other medications, causing either 
potentially dangerous side effects and / or reduced benefits from the 
medications.  Currently, there is very little information published on herb-
drug interactions whilst the use of herbs is progressively growing across the 
world. (Mohammad Yaheya and Ismail; 2009 )A drug interaction occurs 
when a patient’s response to a drug is modified by food, nutritional 
supplements, formulation excipients, environmental factors, other drugs or 
disease. Drug interactions cause medications to be less or more potent than 
intended. Drug interactions can also result in unexpected side effects, which 
may be harmful. These may occur out of accidental misuse or due to lack of 
knowledge about the active ingredients involved in the relevant substances 
(Bushra et al, 2011). Typically, interaction between drugs comes to mind 
(drug-drug interaction). However, interactions may also exist between drugs 
& foods (drug-food interactions), as well as drugs & herbs (drug-herb 
interactions). The mechanisms for drug interaction can be divided into 
several general categories: pharmacokinetics (absorption, distribution, 
metabolism, and excretion of a drug) and pharmacodynamic interactions 
(Barbara, 2006). Pharmacokinetic interactions result from alterations in a 
drug’s absorption, distribution, metabolism, or excretion characteristics. 
These interactions affect drug action by quantitative alterations, either 
increasing or decreasing the amount of drug available to have an effect. 
Pharmacodynamic interactions are a result of the influence of combined 
treatment at a site of biological activity and yield altered pharmacological 
actions at standard plasma concentrations. Although drug interactions occur 
through a variety of mechanisms, the effects are the same: the potentiation or 
antagonism of the effects of drugs. It is difficult to assess the true incidence 
and clinical significance of drug interactions. Understanding the mechanisms 
underlying drug interactions is important for the prediction and avoidance of 
drug toxicity when initiating combination therapy (Stephen, Keith, and 
Manjunath; 2011). 
 Diabetes mellitus is a major health problem and an important cause 
of prolonged ill health and early death (Mutalik and Udupa, 2006). It is a 
chronic metabolic disorder characterized by hyperglycemia (elevated blood 
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glucose level) resulting from defects in insulin secretion, insulin action, or 
both. It is also characterized by disturbances in carbohydrate, fat and protein 
metabolism. The vast majority of cases of diabetes fall into two broad 
etiopathogenetic categories. In one category, type 1 diabetes, the cause is an 
absolute deficiency of insulin secretion. In the other, much more prevalent 
category, type 2 diabetes, the cause is a combination of resistance to insulin 
action and an inadequate compensatory insulin secretory response.Long-term 
complications of diabetes include retinopathy with potential loss of vision; 
nephropathy leading to renal failure; peripheral neuropathy with risk of foot 
ulcers, amputations, and Charcot joints; and autonomic neuropathy causing 
gastrointestinal, genitourinary, and cardiovascular symptoms and sexual 
dysfunction. Patients with diabetes have an increased incidence of 
atherosclerotic cardiovascular, peripheral arterial, and cerebrovascular 
disease. Type 2 diabetes is the most common form of diabetes mellitus, 
accounting for approximately 90% of cases and affecting about 100 million 
people in the word. Projection indicates that there will be over 450 million 
type 2 diabetic patients by the year 2030 (International Diabetes Federation, 
2011. Wild et al, 2004). Men with diabetes tend to develop erectile 
dysfunction 10 to 15 years earlier than men without diabetes. As men with 
diabetes age, erectile dysfunction becomes even more common. Though 
diabetes and Erectile Dysfunction are two separate conditions, they tend to 
go hand-in-hand. According to the National Institute of Diabetes and 
Digestive and Kidney Diseases, men with diabetes are two to three times 
more likely to develop erectile dysfunction. In many cases, problems with 
achieving or maintaining an erection is an early clue that you may be 
diabetic, particularly in men 45 and under. Diabetes mellitus is a metabolic 
disorder in which prolonged treatment is necessary. Maintenance of normal 
blood glucose level is essential in this condition, since both hyperglycemias 
as well as hypoglycemia are unwanted effects. An ideal antidiabetic drug 
would be the one that not only does control the glycemia level but also 
prevents the development of complications (Schernthaner, 2003). Oral 
hypoglycemic agents like sulphonylureas are still the major players in the 
management of type 2 diabetes. Gliclazide is an oral hypoglycemic 
(antidiabetic drug) and is classified as a sulfonylurea. Its classification has 
been ambiguous, as literature uses it as both a first generation (Ballagi et al., 
1990) and second generation (Shimoyama et al., 2006) sulfonylurea. 
Gliclazide was shown to protect human pancreatic betacells from 
hyperglycemia induced apoptosis (Del Guerra et al., 2007). It was also 
shown to have an antiatherogenic effect (preventing accumulation of fat in 
arteries) in type 2 diabetes. (Katakami et al., 2004). Gliclazide is used when 
diabetes cannot be controlled by proper dietary management and exercise or 
when insulin therapy is not appropriate. Gliclazide is available as oral tablets 
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(30 and 80 mg strength) with the recommended dosage between 40 and 
320 mg/day. Reports from the in vivo studies show that, after oral 
administration, gliclazide is almost completely absorbed (Delrat et al, 2002; 
Najib et al, 2002). However, due to its low and pH-dependent aqueous 
solubility (Hong et al, 1998; Özkan et al, 2000; Shewale et al, 2008), 
Gliclazide absorption rate appears to be slow and variable (Hong et al, 1998; 
Kobayashi et al, 1981; Davis et al, 2000; Rana, 2010), and therefore, its 
absorption profile is difficult to decipher. 
 Herb is plant or plant part used for its scent, flavor, or therapeutic 
properties. Herbal medicines are one type of dietary supplement. They are 
sold as tablets, capsules, powders, teas, extracts, and fresh or dried plants. 
People use herbal medicines to try to maintain or improve their health. Many 
people believe that products labeled "natural" are always safe and good for 
them. This is not necessarily true. Herbal medicines do not have to go 
through the testing that drugs do. Some herbs, such as comfrey and ephedra, 
can cause serious harm. Some herbs can interact with prescription or over-
the-counter medicines. Herbal sex stimulants for Men contains a selection of 
herbs (John, 2007) from around the world and which are traditionally 
identified as having aphrodisiac properties and are safe and non-addictive. 
They are known for their supportive function in maintaining sexual health 
and well-being. Herbal sex stimulants for men is used for strong erections 
without risk of side effects, maintain sexual arousal, drive and desire, 
promotes systemic and hormonal balance. Male impotence also called 
Erectile dysfunction is considered as one of the most important public health 
problems, since it affects a great percentage of men worldwide. Erectile 
dysfunction is defined as the consistent inability to obtain or maintain an 
erection for satisfactory sexual relations. An estimated 20-30 million men 
suffer from some degree of sexual (Gallé and Trummer, 2003). It occurs 
commonly in middle-aged and older men. Impotence occurs in 50% of men 
with diabetes mellitus. Erectile dysfunction is also associated with some 
therapeutic agents like antihypertensives, antipsychotics, antidepressants, 
and drugs for diabetes mellitus (Pallavi et al., 2011; Guay et al., 20003; 
Martey, 2010).Treatment of Erectile dysfunction involves several natural 
aphrodisiac potentials. Aphrodisiac is described as any substance that 
enhances sexual pleasure.Plants like Bhindi, Musk mallow, Peanut, Garlic, 
Chiense chive, Punarnava, Capsicum, Coconut, Carrot, Ginseng, Ginger, 
West African Pepper, Gingembre and many other herbs found worldwide has 
aphrodisiac properties, hence used as sex stimulants for men (Pallavi et al., 
2011). Herbal sex stimulants are found in different dosage forms like tablets, 
capsules, powder, and cream. 
 Therefore, the objective of the present work is to identify any drug 
interaction between oral hypoglycemic drugs with herbal sex stimulants. 
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Drug-herbal interactions can occur at the pharmaceutical, pharmacodynamic 
or pharmacokinetic levels (Beijnen and Schellens, 2004) but most of the 
interactions occur at pharmacokinetic level (Brazier and Levine, 2003) that 
involves changes in absorption, distribution, metabolism and excretion of the 
conventional drug, which in turn determine the bioavailability of the drug. 
The use of adulterated herbal medicines sometimes result in serious ailments 
such as acute renal failure (De Smet, 1995; Abt et al., 1995; Nelson et al., 
1995; Gertner et al., 1995; Van et al., 1994). In the present study, release 
kinetics of oral hypoglycemic drug (e.g. glyclazide) was determined alone 
and in presence herbal sex stimulants to understand the drug interactions.  
 
Materials, methods and equipments 
Materials 
 Gliclazide (designated as Gli) tablets of one brand and the innovator 
brand with labeled contents of 80 mg and five different herbal sex stimulants 
tablets (designated as H1, H2, H3, H4, H5, and H6) for men according to 
Bangladesh National Formulary of Unani Medicine were obtained from local 
market of Bangladesh. All the drugs were checked for their production and 
expiry dates. Purified water used throughout the research. Other materials 
used for analysis were also purchased from local market and these were all 
analytical grade. 
 
List of Equipments 
• Electronic balance 
• USP Dissolution apparatus – ІІ 
• UV Visible spectrometer 
 
In vitro Dissolution study  
 In-vitro dissolution study of gliclazide and gliclazide with herbal 
drugs was carried out in a USP Type II (paddle type) dissolution apparatus. 
Simulated gastric medium of pH 1.2 and Phosphate buffer pH 7.4 were used 
in separate experiment as dissolution medium that was maintained at 37± 
0.5°C and stirred at 100 revolutions per minutes (rpm). At predetermined 
time intervals, 10-ml sample was withdrawn and replaced with fresh 
dissolution medium.  After filtration and appropriate dilution, the sample 
solution was analyzed at 226 nm and 290 nm using respective blank solution 
in a reference cell. Correct the absorbance obtained at 226 nm by subtracting 
the absorbance obtained at 290 nm. The dissolution study was continued for 
8 hours in each experiment to get a simulated picture of the drug release in 
the in-vivo condition. The drug release profile was fitted into several 
mathematical models to get an idea of the release mechanism and drug 
interaction.  
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Kinetics modeling of drug release 
 Different kinetic models (zero order, first order and Higuchi 
equation) were applied to analyze the mechanism of drug release-rate 
kinetics. Mathematical modeling increases understanding of the release 
mechanism and in turn helps to identify drug interactions. Here, in vitro drug 
release data obtained from the dissolution studies of gliclazide tablets only 
and gliclazide with herbal sex stimulants were fitted to zero order, first order 
and Higuchi equation to ascertain the kinetic modeling of drug release and 
drug interaction.  
 
Zero Order Kinetics 
 Zero-order (Wagner, 1969) release kinetics describes systems where 
the drug release rate is constant over a period of time and it is the ideal 
method of drug release in order to achieve a pharmacological prolonged 
action. The zero-order release kinetics can, in a simple way, express by 
following equation: 
Qt = Qo + Ko t 
Where, 
 Qt  = amount of drug released in time ‘t’ 
 Qo = initial amount of drug in the solution, 
 Ko = zero order release constant 
 A plot of amount of drug released versus time will be linear for zero-
order kinetics. The dosage forms following this profile, release the same 
amount of drug by unit time and it is the ideal method of drug release in 
order to achieve a prolonged pharmacological action. This relation can be 
used to determine the drug dissolution from various types of modified 
release dosage forms such as matrix tablets with low soluble drugs, coated 
tablets and capsules and osmotic systems.  
 
First Order Kinetics 
 The application of this model to drug dissolution studies was first 
proposed by Gibaldi and Feldman (1967) and later by Wagner (1969). In 
typical first-order release kinetics, the drug release rate depends on its 
concentration. The first order release kinetics can be expressed by following 
equation: 
Log Qt = Log Qo + Kt /2.303 
Where, 
 Qt  = amount of drug released in time ‘t’. 
 Qo = initial amount of drug in the solution,  
 Kt  = first order release constant 
 Here, the graphical representation of the log cumulative of % drug 
remaining versus time will be linear with a negative slope. The dosage form 
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follows this profile such as those containing water soluble drug in a porous 
matrices, release the drug that is proportional to the amount of drug released 
by unit time diminish. 
  
Higuchi Model 
 A descriptive mathematical model for drug dissolution from matrix 
systems was not developed until 1961 by Higuchi. The model was initially 
derived for planar systems; however it has since been modified for use with 
different geometries and porous systems. The most familiar form of the 
Higuchi model is the simplified Higuchi model, which relates drug 
concentration to the square root of time: 
ft = KH t1/2 
Where,  
ft    = Concentration of drug in the drug matrix at time ‘t’ 
KH = Higuchi dissolution constant 
  
Results and discussion 
 To investigate the drug interaction of oral hypoglycemic drug (e.g. 
gliclazide) with herbal sex stimulants for men we performed in vitro 
dissolution study and different kinetic model also studied. Oral 
administration of gliclazide and concomitant administration of herbal sex 
stimulants might bring some relative changes in release kinetics of 
gliclazide. 
 
Kinetic modeling of drug release 
 Drug release data obtained were extrapolated by Zero order, First 
order and Higuchi equations to know the mechanism of drug release and 
drug interaction. 
 In case of Zero order rate kinetics (cumulative amount of drug 
released versus time; Figure-1 a, b), it was observed that the percent release 
of gliclazide increased with time (for 8 hours) at simulated pH medium of 
1.2 & 7.4. A burst release observed within first hour. Higher percent release 
of gliclazide observed at pH7.4 than pH1.2. Slightly higher percent release of 
gliclazide also observed in presence of herbal sex stimulants than than 
gliclazide alone. 
 In case of First order rate kinetics (log cumulative percentage of drug 
remaining versus time; Figure-1 c, d), it was observed that the log of percent 
remaining of gliclazide decreased with time (for 8 hours). It is also observed 
that in presence of herbal sex stimulants log of percent remaining of 
gliclazide decreased more with time at different simulated pH medium of pH 
1.2 and pH 7.4. 
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 In case of Higuchi release kinetics (cumulative percentage of drug 
released versus square root of time; Figure-e, f) it was observed that the 
percent release of gliclazide and gliclazide in presence of herbal sex 
stimulants increased with square root of time (for 8 hours) at different 
simulated pH medium (pH 1.2 and pH 7.4). Slightly higher percent release of 
gliclazide observed in presence of herbal sex stimulants than that of 
gliclazide alone. 
 




From the results (Figure-1 & 2) it is clearly demonstrated that the 
percent (%) release gliclazide increased with time and a burst release 
observed within first hour. It is also observed that the percent release of 
gliclazide increased more in presence of herbal sex stimulants as well as with 
the increase of pH which indicated that the increase in absorption of 
gliclazide in presence of herbal sex stimulants. But slightly higher percent 
release of gliclaide observed in presence of different herbal sex stimulants at 
the present study. Since the percent (%) release of gliclazide was not 
significantly changed in presence of herbal sex stimulants comparing to 
gliclazide alone, which gives us an idea that if we takes this two drug 
concurrently there will be no hazardous effect from each other. 
 
Conclusion & future plan 
 According to the release study, the higher percent release of oral 
hypoglycemic drug (gliclazide) in presence of different herbal sex stimulants 
at different simulated medium (pH 1.2 and pH 7.4) indicating a drug 
interaction. But the significant difference of percent release between oral 
hypoglycemic drug (gliclazide) and oral hypoglycemic drug (gliclazide) in 
presence of herbal sex stimulants is not observed; suggesting the interaction 
is not harmful. It is difficult to assess the true incidence and clinical 
significance of drug interactions. Understanding the mechanisms underlying 
drug interactions is important for the prediction and avoidance of drug 
toxicity when initiating combination therapy. The process of using in vitro 
models to predict in vivo drug interactions is still in its infancy, and extensive 
validation of this approach is needed. In vitro models predictive of in vivo 
drug interactions will be essential for rapid, cost-effective screening of 
pharmaceutical compounds and are important for reducing risks to patient 
safety. So further wide scale study is necessary underlying the present drug 
interaction.  
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